iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Raman-based imaging can help clinicians distinguish tumor-containing tissue from nearby tissue during some operations, but it is not a general cancer-screening test. The strongest recent human evidence in this material is a multicenter study of selected brain tumors; it reports promising classification accuracy, not proof that Raman imaging improves survival or is ready for routine use across cancers.
Why use Raman imaging during cancer surgery?
Tumor and healthy tissue can look alike to the naked eye. During an operation, a surgeon may need rapid information about whether tissue contains cancer, especially when assessing a tumor’s boundaries or a biopsy specimen. Conventional pathology remains an important reference, but preparing and examining tissue can take time.
Raman spectroscopy measures light scattered by molecular vibrations. The resulting pattern acts as a chemical fingerprint: differences in tissue composition can help a classifier distinguish tumor-containing from non-tumoral tissue. It is called label-free when the measurement does not rely on adding an external dye or contrast agent.
That describes a way to characterize tissue, not a standalone cancer diagnosis for every patient. Performance depends on the device, cancer type, workflow, and the patients and samples used to evaluate it.
#1 Best Overall
Raman spectroscopy and Raman histology are not the same workflow
| Approach | What it measures or images | Setting described in the evidence |
|---|---|---|
| Spontaneous Raman spectroscopy | Raman signal collected at a measurement point to characterize tissue. | Can be measured in situ during surgery; the 2024 brain-tumor study assessed this approach. |
| Stimulated Raman histology (SRH) | Stimulated Raman signals are used to create microscopy images of fresh tissue. | Images a fresh-tissue specimen; Invenio describes this workflow for its NIO system. |
These methods share Raman contrast but are not interchangeable. Measuring tissue in the patient, imaging a removed specimen, assessing a biopsy, and evaluating a tumor margin are distinct tasks. Evidence for one workflow does not automatically validate another.
What human studies have reported
A multicenter study of brain tumors
A 2024 multicenter study evaluated the Sentry system during open brain-tumor surgery in 67 adults, with 976 in-situ measurements. Investigators reported diagnostic accuracy of 91% for glioblastoma, 97% for brain metastases, and 96% for meningiomas. These are study-specific results for the tumors, system, and surgical setting examined, not guaranteed performance in other hospitals or cancers. Read the 2024 study in Scientific Reports.
Rank #2
The patient count and measurement count are different: 976 measurements were collected from 67 adults. The results support feasibility and classification performance in that setting; they do not establish how well the system would work in population screening or prove that using it improves patient outcomes.
Free tools Windows power users keep installed
One-click scans. No signup required.
A multimodal study across several cancer types
A 2017 study reported 97% accuracy, 100% sensitivity, and 93% specificity for a system tested on specimens from brain, lung, colon, and skin cancers. Those figures belong to a device combining Raman spectroscopy with intrinsic fluorescence and diffuse reflectance. They should not be presented as the performance of Raman alone. The investigators also reported eight seconds of total imaging time for their system; that is a study-specific workflow figure, not a general Raman scan time. Read the 2017 study in Cancer Research.
Accuracy, sensitivity, and specificity measure different things. Accuracy is the share of classifications that are correct overall; sensitivity measures how often cancer-containing samples are identified; specificity measures how often non-cancer samples are correctly identified. Results can also depend on the mix of cases in the study, so a number from a selected surgical cohort should not be carried over to a different population or screening setting.
What a commercial SRH system illustrates—and what it does not
Invenio Imaging markets the NIO Laser Imaging System for fresh-tissue stimulated Raman histology. The company says its workflow can produce images in three minutes or less and describes sample preparation without staining or sectioning, along with digital image sharing. These are manufacturer statements, not independent estimates that apply to all Raman systems. See Invenio’s NIO product information.
Invenio’s product page says its Glioma Reveal image-analysis module is available for clinical use in the EU and is “For Research Use Only” in the United States, not for diagnostic procedures. That is the company’s stated regional status; intended use and authorization must be checked for the specific product and jurisdiction.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsThe company has also announced FDA Breakthrough Device Designation for an AI image-analysis module intended to assist evaluation of bronchoscopic lung biopsies. Breakthrough designation is not FDA clearance or approval. Invenio announced CE marking for NIO in 2021 under the then-applicable In Vitro Diagnostic Directive; that historical announcement alone does not establish the system’s present status under current European rules. See Invenio’s press announcements.
Best Value
- Used Book in Good Condition
What Raman cancer imaging has not established
- A population screening role: The cited human evidence concerns tissue assessment in surgical or specimen workflows, not screening asymptomatic people.
- Universal performance: The reported results are tied to particular systems, tumor types, cohorts, and clinical settings. They do not show that every Raman device performs similarly.
- Improved outcomes: Classification accuracy by itself does not show that clinicians make better decisions or that patients live longer or avoid complications.
- Routine availability everywhere: Clinical status depends on the specific system, intended use, software, and geography. A research-use statement, CE marking announcement, or FDA Breakthrough designation should not be mistaken for general authorization.
Reviews describe continued development of label-free optical methods for tumor-margin assessment and endoscopic cancer imaging, while noting translation and miniaturization as practical considerations. That broader promise is not evidence of routine adoption or proven patient benefit. See the 2024 Annual Reviews discussion of label-free optical technologies; see a 2025 review of label-free microscopic imaging in oncological surgery.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
